JA
NKTR icon

JOYN Advisors’s Nektar Therapeutics NKTR Stock Holding History

JOYN Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed -$6K – 946
2018
Q4 		$6K Buy
13
+11
+550% +$6.64K ﹤0.01% 1189
2018
Q3 		$2K Buy
2
+1
+100% +$854 ﹤0.01% 1477
2018
Q2 		$0 Sell
1
-1
-50% -$1.15K ﹤0.01% 1828
2018
Q1 		$2K Buy
+2
New +$2.58K ﹤0.01% 1082

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JOYN Advisors's NKTR Position: Q1 2019 in Review

JOYN Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 13 shares — an estimated $6K sold.

JOYN Advisors first reported a position in NKTR in Q1 2018 and held it in 4 quarters. The position peaked at $6K in Q4 2018. 349 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • JOYN Advisors reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • JOYN Advisors sold 13 Nektar Therapeutics shares in Q1 2019, an estimated $6K.
  • JOYN Advisors first reported a position in Nektar Therapeutics in Q1 2018 and held it in 4 quarters.
  • JOYN Advisors's Nektar Therapeutics position peaked at $6K in Q4 2018.
  • 349 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.